Drugs / SPL84
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT06217952 Comparator | Feb → Aug 2023 | cystic fibrosis | SpliSense Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT06429176 Comparator | Jun 2024 → Oct 2027 expected | cystic fibrosis | SpliSense Ltd. | Recruiting | No outcome recorded |
Press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-03-04 | SpliSense Ltd. | SpliSense Granted EMA EARLY PRIME Designation for SPL84 in Cystic Fibrosis splisense.com ↗ |
| 2025-09-09 | SpliSense Ltd. | SpliSense Reports Positive Results from Phase 2 Study of SPL84 splisense.com ↗ |
| 2024-04-04 | SpliSense Ltd. | SpliSense Announces FDA Clearance of Investigational New Drug Application for Phase 2 Initiation of SPL84 for the Treatment of Cystic Fibrosis splisense.com ↗ |
| 2022-12-21 | SpliSense Ltd. | SpliSense Initiates Phase 1/2 Study of SPL84, RNA-Based Therapy, for the Treatment of Cystic Fibrosis splisense.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SPL84 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06217952 ↗ |
| Route | Inhaled | “Participants will take drug SPL84 or a placebo by inhalation every week” NCT06429176 ↗ |